Evidence map›Paper›PMID 17786047›Full record

ArticleCell cycle (Georgetown, Tex.)2007

Replicational stress selects for p53 mutation.

Andriy Marusyk, James DeGregori

Open access · bronzeAbstract read
In one paragraph

Article in Cell cycle (Georgetown, Tex.), 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.1field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Andriy MarusykDepartment of Biochemistry and Molecular Genetics, Program in Molecular Biology, University of Colorado at Denver Health Sciences Center, Aurora, Colorado 80045, USA.
James DeGregori
University of Colorado Hospital · US

Funding

Poor competition in hematopoietic stem/progenitor pools favors tumorigenesisR01CA109657 · NCI · UNIVERSITY OF COLORADO DENVER · PI DEGREGORI, JAMES V · 2005 to 2009
$1.1M
NCI NIH HHS R01 CA109657
6 · The paper itself

Abstract

p53 is a critical mediator of cellular responses to a variety of stresses. Given the frequency of p53 mutations in human malignancies and that disruption of p53 has been implicated in chemoresistance, understanding the factors that select for p53 disruption is important both for understanding tumor evolution and for designing cancer therapies. While it is widely believed that genotoxic stress selects for p53 mutations, the effects of DNA damaging agents on long-term proliferative potential are usually not affected by p53 status. Previous reports have demonstrated that despite being activated, p53 loss does not prevent cell cycle arrest and senescence in response to high levels of acute replicational stress. In contrast, we recently reported that chronic exposure of non-transformed cells to low, clinically relevant levels of replicational stress induces p53-dependent senescence-like arrest. Disruption of p53 or its target gene p21(CIP1) antagonizes this arrest, leading to a long-term proliferative advantage. However, when replicational stress is associated with substantial DNA strand breaks, the ability of p53 disruption to up-regulate RAD51 dependent homologous recombination becomes important. Replicational stress is induced by many chemotherapeutic treatments and perhaps by some dietary deficiencies, and may be an important factor that selects for p53 mutations during cancer initiation and progression.

Indexed as

DNA ReplicationAnimalsCell ProliferationCellular SenescenceCyclin-Dependent Kinase Inhibitor p21EtoposideHumansHydroxyureaMiceMutationOncogenesRad51 RecombinaseTumor Suppressor Protein p53Cyclin-Dependent Kinase Inhibitor p21EtoposideHydroxyureaRad51 RecombinaseTumor Suppressor Protein p53

Identifiers

PMID17786047
PMCPMC2394679
OpenAlexW1967297795

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.